CanSino Biologics prepares to advance COVID-19 vaccine candidate into phase II trial

Based on preliminary safety data from Phase I clinical trial the company is planning to initiate a mid-stage trial in China of its adenovirus type 5 vector, Ad5-nCoV, as a potential vaccine candidate, putting the company ahead of others in the race to develop a vaccine.


Biospace Inc.